GlassScriptPhysician profile
Elli J Roberts
NPI 1578953162
$8,320.83
in general payments reported to CMS, 2019-2025
32 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $2,044 · 2023: $2,641 · 2024: $2,232 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,083.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,395.07 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,100.07 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $781.10 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $639.47 | 2022-2025 | |
| Corcept Therapeutics | $631.60 | 2022-2025 | Korlym |
| Radius Health, INC. | $430.72 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.87 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $298.31 | 2021-2025 | Lokelma, Tezspire, Farxiga |
| Tandem Diabetes Care, INC. | $282.61 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $279.93 | 2022-2025 | Unithroid |
| Abbvie INC. | $247.86 | 2021-2025 | |
| Ascensia Diabetes Care US INC. | $230.23 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $209.59 | 2023-2025 | |
| Dexcom, INC. | $198.58 | 2023-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $162.60 | 2022-2025 | Afrezza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $141.44 | 2022-2024 | |
| Cequr Corporation | $140.80 | 2023-2024 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $126.51 | 2023-2025 | Isturisa, Signifor Lar |
| Amgen INC. | $102.64 | 2023-2025 | Evenity, Prolia, Tepezza |
| Alexion Pharmaceuticals, INC. | $85.29 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $81.17 | 2022-2023 | Steglatro, Steglujan |
| Xeris Pharmaceuticals, INC. | $77.85 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Ibsa Pharma INC. | $67.91 | 2023-2025 | Tirosint, Licart, Tirosint |
| Medtronic, INC. | $28.83 | 2022 | |
| Ascendis Pharma Endocrinology INC | $28.06 | 2025 | Yorvipath |
| Amarin Pharma, INC. | $23.97 | 2022 | |
| Sequel Med Tech, LLC | $22.69 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $20.37 | 2022 | |
| Sanofi Pasteur INC. | $16.81 | 2021 | |
| Daiichi Sankyo INC. | $16.19 | 2021 | |
| Eisai INC. | $15.45 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elli Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.